Oclacitinib 10 years later: lessons learned and directions for the future.

Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in dogs. Many studies and case reports have been published in the past 10 years on the efficacy and safety of this medication, both at labeled doses to treat allergic dogs and off label to treat other diseases and given to other species. Concerns and confusion have occurred for both clinicians and owners regarding the long-term safety of this drug. The purpose of this review is to present the current knowledge on the efficacy, speed of action, effects on the immune system, and clinical safety of oclacitinib, based on evidence and published literature. We also aim to summarize the lessons learned in the past 10 years and to propose directions for the future.

[1]  Ina Herrmann,et al.  Long-term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T-cells, IL-10 and TGF-β, in dogs with atopic dermatitis. , 2022, Veterinary dermatology.

[2]  R. Malik,et al.  Fatal disseminated toxoplasmosis in a feline immunodeficiency virus‐positive cat receiving oclacitinib for feline atopic skin syndrome , 2022, Veterinary dermatology.

[3]  J. Fontaine,et al.  Inherited Sensory and Autonomic Neuropathy in a Border Collie, Interest of Oclacitinib for the Control of Self-Mutilation , 2022, Veterinary sciences.

[4]  A. Crowley,et al.  A case report of the beneficial effect of oclacitinib in a dog with pemphigus vulgaris. , 2022, Veterinary dermatology.

[5]  V. Fajt,et al.  Pharmacokinetics of a single dose of oclacitinib maleate as a top dress in adult horses. , 2022, Journal of veterinary pharmacology and therapeutics.

[6]  M. De Lucia,et al.  Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs. , 2022, Veterinary dermatology.

[7]  K. Shiomitsu,et al.  Cytokine production and the effects of oclacitinib in three canine mast cell tumour cell lines. , 2021, Veterinary dermatology.

[8]  L. Ferrer,et al.  Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response , 2021, Journal of feline medicine and surgery.

[9]  J. Jaroszewski,et al.  Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-γ-, Producing Murine CD4+ and CD8+ T Cells and Counteracts the Induction of Type 1 Regulatory T Cells , 2021, Molecules.

[10]  S. Colombo,et al.  Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series. , 2021, Veterinary dermatology.

[11]  M. Shipstone,et al.  Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report. , 2021, Veterinary dermatology.

[12]  G. Albinyana,et al.  Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus. , 2021, Veterinary dermatology.

[13]  G. Cousandier,et al.  Juvenile-Onset Ischemic Dermatopathy in a Dog , 2021 .

[14]  R. S. Soares Magalhaes,et al.  The Association Between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study , 2021, Frontiers in Veterinary Science.

[15]  2020 ACVIM Forum On Demand Research Abstract Program , 2020, Journal of veterinary internal medicine.

[16]  W. Rosenkrantz,et al.  Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib. , 2020, Journal of the American Veterinary Medical Association.

[17]  Ina Herrmann,et al.  Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogs. , 2020, Veterinary dermatology.

[18]  R. Marsella,et al.  Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs. , 2020, Veterinary dermatology.

[19]  L. Ferrer,et al.  A pharmacokinetic study of oclacitinib maleate in six cats. , 2019, Veterinary dermatology.

[20]  F. Montiani-Ferreira,et al.  Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca. , 2019, Veterinary ophthalmology.

[21]  C. London,et al.  Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study , 2019, BMC Veterinary Research.

[22]  T. Olivry,et al.  The role of oclacitinib in the management of ischaemic dermatopathy in four dogs. , 2019, Veterinary dermatology.

[23]  F. Scott,et al.  A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats , 2019, BMC Veterinary Research.

[24]  C. Noli,et al.  A double‐blinded, randomized, methylprednisolone‐controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood‐induced hypersensitivity dermatitis , 2019, Veterinary dermatology.

[25]  J. Pieper,et al.  Urticaria pigmentosa-like skin disease in a domestic shorthair cat , 2019, JFMS open reports.

[26]  J. Jaroszewski,et al.  Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro. , 2018, Research in veterinary science.

[27]  R. Gogal,et al.  Immunomodulatory in vitro effects of oclacitinib on canine T‐cell proliferation and cytokine production , 2018, Veterinary dermatology.

[28]  Clarissa P Souza,et al.  A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA , 2018, Veterinary dermatology.

[29]  R. Marsella,et al.  A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs , 2018, Veterinary dermatology.

[30]  Z. Lu,et al.  JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B‐Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation , 2017, Journal of veterinary internal medicine.

[31]  T. Nuttall,et al.  TREATMENT SUCCESS IN THREE ANDEAN BEARS (TREMARCTOS ORNATUS) WITH ALOPECIA SYNDROME USING OCLACITINIB MALEATE (APOQUEL®) , 2017, Journal of zoo and wildlife medicine.

[32]  Gotthelf Ln.  Efficacy of APOQUEL® for the Control of Otitis Externa Secondary to Allergic Skin Disease in Client-Owned Dogs , 2017 .

[33]  A. Manchester,et al.  Acute respiratory distress syndrome and septic shock in a cat with disseminated toxoplasmosis. , 2017, Journal of veterinary emergency and critical care.

[34]  E. Bensignor,et al.  A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib. , 2017, Veterinary dermatology.

[35]  R. Rosychuk,et al.  The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study , 2017, Veterinary dermatology.

[36]  S. Cohen,et al.  Malignancy and Janus Kinase Inhibition. , 2017, Rheumatic diseases clinics of North America.

[37]  S. Mahabir,et al.  A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. , 2016, Veterinary dermatology.

[38]  S. Feldman,et al.  Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial , 2016, BMC Dermatology.

[39]  T. Barbui,et al.  Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis , 2016, Leukemia.

[40]  R. Mccall,et al.  IL‐31‐induced pruritus in dogs: a novel experimental model to evaluate anti‐pruritic effects of canine therapeutics , 2015, Veterinary dermatology.

[41]  Domenico Santoro,et al.  Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification , 2015, BMC Veterinary Research.

[42]  C. Noli,et al.  Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats. , 2015, Veterinary dermatology.

[43]  J. Snowden,et al.  The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours , 2015, British Journal of Cancer.

[44]  M. Stegemann,et al.  Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. , 2015, Veterinary dermatology.

[45]  M. Stegemann,et al.  A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs , 2014, Veterinary dermatology.

[46]  M. Stegemann,et al.  Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia , 2014, Veterinary dermatology.

[47]  J. Boucher,et al.  The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. , 2014, Journal of veterinary pharmacology and therapeutics.

[48]  A. Gonzales,et al.  Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy , 2014, Journal of veterinary pharmacology and therapeutics.

[49]  J. Tena,et al.  A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis , 2013, Veterinary dermatology.

[50]  J. Boucher,et al.  Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis , 2013, Veterinary dermatology.

[51]  A. Kristensen,et al.  Mast cell tumours and other skin neoplasia in Danish dogs - data from the Danish Veterinary Cancer Registry , 2010, Acta veterinaria Scandinavica.

[52]  D. Santoro,et al.  Investigation on the association between atopic dermatitis and the development of mycosis fungoides in dogs: a retrospective case-control study. , 2007, Veterinary dermatology.

[53]  Yasuhiro Suzuki,et al.  A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin A for feline atopy. , 2004, Veterinary dermatology.

[54]  J. Beatty,et al.  Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporin therapy. , 2006, Australian veterinary journal.